As the most challenging disease to spell and pronounce continues its global expansion, access to the only approved chikungunya virus vaccine is becoming broader.
The Coalition for Epidemic Preparedness Innovations (CEPI) has expanded its support to provide expanded access to the world’s first chikungunya vaccine, IXCHIQ®.
IXCHIQ (VLA1553) is a monovalent, single-dose, live-attenuated chikungunya vaccine that the U.S. Food and Drug Administration approved in November 2023.
$41.3 Million Supports Increased Access to the First Chikungunya Vaccine
Two Mosquito-Transmitted Viruses Causing Microcephaly in Newborns
According to the Pan American Health Organization (PAHO), scientists in Brazil believe that the Oropouche virus (OROV) may cause stillbirths and neurological defects in babies who are infected in the womb, similar to the Zika virus.
Since 2013, 31 countries and territories in the Americas have reported cases of microcephaly (head shape issues) and other central nervous system malformations associated with Zika infection.
Fewer Mental Health Facilities Offering Telehealth Since End of Pandemic
Declines seen in scope and modality of services
COVID-19 Infection, Vaccination Not Linked to Congenital Anomalies
In study of infants from Sweden, Denmark, and Norway, no link seen for infection or vaccination in the first trimester with congenital anomalies
Plain Language Review Explains Innovative Bladder Cancer Therapy
A recent Plain Language Summary of Publication stated ImmunityBio Inc.'s newly approved Anktiva® (N-803) plus Bacillus Calmette-Guérin (BCG) vaccine combination therapy produced positive results for certain bladder cancer patients.
Postexposure Prophylaxis With Nirmatrelvir-Ritonavir Does Not Cut COVID-19 Infection
No significant reduction seen in risk for symptomatic SARS-CoV-2 infection with postexposure prophylaxis for five or 10 days
Accelerated Progression to T1D During Pandemic Seen for Presymptomatic Youth
Incidence rate of type 1 diabetes significantly increased after COVID-19 infection
Severity of COVID-19 Reinfection Linked to Severity of Initial Infection
Within the same epoch, long COVID diagnoses occur more often following initial infection than reinfection
Lyme Disease Vaccine Candidate Approaches Approval
Lyme disease has been a nationally notifiable condition in the United States since 1991 without a U.S. Food and Drug Administration (FDA) approved vaccine.
Initially identified in Lyme, Connecticut, in 1976, over 63,000 cases of Lyme disease were reported by state health departments and the District of Columbia in 2022, primarily in the northeastern U.S.
However, based on the continued positive progress of an innovative multivalent protein subunit Lyme disease vaccine candidate, nature lovers may soon gain protection from this Black-legged tick-borne disease.
Another Country Offers Second-Gen Malaria Vaccine
In collaboration with UNICEF, the World Health Organization (WHO), and Gavi, South Sudan's Ministry of Health, today announced the official launch of a nationwide R21/Matrix-M™ malaria vaccine distribution.